Our vision is to be the most customer-centric CRO on earth. We are conscious that our customers look for ways to accelerate trial execution. So we deliver on our vision by delivering faster, smarter, scientific and affordable solutions.
We work vigorously to design patient- and PI-centric trials, to reduce the trial delivery timelines and costs and to drive smarter decision-making processes through data insights. Pivotal was born and raised in 2001 surrounded by an environment of high scientific tenure and drive. Our founder, Dr. Ibrahim Farr, launched Pivotal to share and implement scientific strategies and best project practices that make clinical trials more efficient and maximize our client’s drug development programs’ value chain.
As a company with some 200 employees and operating in more than 20 countries we have built focused specialization across all therapeutic areas and founded a strong innovative therapies and early phases hub that enables us to tackle our customers most difficult challenges. After almost 22 years of hands-on experience, we master clinical research.
Pivotal has forged an aspirational vision of a digitally and data-enabled, growth-oriented future. We dive deep into clinical trials by leveraging our near real time advanced insights platform. We discover data-driven insights to anticipate trial risks and predict their impact. This has made us an efficient, agile and resilient company, very focused on our customers. We are a technology-savvy organization.
Our approach to clinical research can be summarized in our Innovative Organizational Model: connected with the clinical research and technology ecosystem, scientifically, medically data-driven, agile and customer-centric.
Lead the firm is our mission of delivering cost-effective and accelerated development solutions.
Pivotal has assembled a strong leadership team that combines unrivaled operational expertise and management experience with a global background. Pivotal’s leadership team contributes to managing growth and direction of the company and is highly committed to the company’s long-term goal and to foster Pivotal’s entrepreneurial culture.
Dr. Ibrahim Farr
Chairman & Chief Executive Officer
MD, PhD, FFPM (UK)
Dr. José Javier García
Deputy General Manager & VP Data Management and Biostatistics
MD
Dr. Lourdes Huarte
VP Clinical Operations
MPharm, PHD, MBA
Ms Lidia Farr
VP Corporate Development & Finance
MSc Engineering
Dr. Ernesto Estefanía
Internal Medicine Medical Director and Head of Pharmacovigilance
MD
Dr. Elisa Galvez, Medical Director, Oncology and Hemato-Oncology Director
Biotechs and Pharma Cos, medical devices, nutrition and others
Retention in Clinical Trials
Pivotal
Clinical Trials in an Intensive Care Unit: Challenges and Successful Implementation
Pivotal
Navigating EU-UK Dual-Track Clinical Trial Regulation in Parallel
Pivotal
Successful Rescue and Accelerated Restart of a Clinical Trial for NTRK-Fusion-Positive Advanced or Metastatic Solid Tumors
Pivotal
AI in drug development. A CRO’s strategic roadmap
Pivotal
Drug-Resistant Focal Epilepsy: Clinical Trials and Emerging Therapies. Transforming Patient Care Through Innovation
Pivotal
Transforming Clinical Data into Actionable Insights
Pivotal
Alzheimer’s Disease Clinical Trials and Emerging Therapies: Transforming Patient Care Through Innovation
Pivotal
Case Study: Accelerating Protocol Development for a European Biotech’s Bi-Specific Antibody Program
Pivotal
Elevating Clinical Development with Specialized Medical Services
Pivotal
